Article in press - uncorrected proof
292 P. Wu et al.
used and bonds involving hydrogen atoms were constrained to their
equilibrium lengths using the SHAKE algorithm (Ryckaert et al.,
1977). From the production simulations, structures were saved every
0.75 ps for analyses, which were done using the ptraj program of
the AMBER9.0 simulation package (Case et al., 2005). The MD
simulations were done using SANDER and PMEMD programs of
the AMBER package. In all the simulations, f99 force-field (Cornell
et al., 1995; Wang et al., 2000) augmented with backbone correc-
tions by Hornak et al. (2006) was used.
Gosalia, D.N., Salisbury, C.M., Ellman, J.A., and Diamond, S.L.
(2005). High throughput substrate specificity profiling of serine
and cysteine proteases using solution-phase fluorogenic peptide
microarrays. Mol. Cell. Proteomics 4, 626–636.
Halfon, S., Baird, T.T., and Craik, C.S. (2004). Trypsin. In: Hand-
book of Proteolytic Enzymes, 2nd edn, A.J. Barret, N.D. Raw-
lings and J.F. Woessner, eds. (London, UK: Elsevier Academic
Press), pp. 1483–1488.
Haverback, B.J., Dyce, B., Bundy, H., and Edmondson, H.A. (1960).
Trypsin, trypsinogen and trypsin inhibitor in human pancreatic
juice. Am. J. Med. 29, 421–433.
Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and
Simmerling, C. (2006). Comparison of multiple Amber force
fields and development of improved protein backbone parame-
ters. Proteins 65, 712–725.
Sequence similarity searches
Proteins harboring similar sequences as the peptides identified in
nlm.nih.gov) (Altschul et al., 1997). The search was restricted to
human proteins in the Swiss-Prot database.
Itkonen, O., Koivunen, E., Hurme, M., Alfthan, H., Schroder, T.,
and Stenman, U.H. (1990). Time-resolved immunofluorometric
assays for trypsinogen-1 and 2 in serum reveal preferential ele-
vation of trypsinogen-2 in pancreatitis. J. Lab. Clin. Med. 115,
712–718.
Acknowledgments
Katona, G., Berglund, G.I., Hajdu, J., Graf, L., and Szilagyi, L.
(2002). Crystal structure reveals basis for the inhibitor resistance
of human brain trypsin. J. Mol. Biol. 315, 1209–1218.
Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the
role of proteases in cancer. Clin. Chim. Acta 291, 113–135.
Koistinen, H., Na¨rva¨nen, A., Pakkala, M., Hekim, C., Mattsson,
J.M., Zhu, L., Laakkonen, P., and Stenman, U.H. (2008). Devel-
opment of peptides specifically modulating the activity of KLK2
and KLK3. Biol. Chem. 389, 633–642.
The authors thank Ms. Helena Taskinen and Ms. Annikki Lo¨fhjelm
for excellent technical assistance. This work was supported by
grants from the University of Helsinki, Helsinki University Central
Hospital, the Finnish Cancer Foundation, the Academy of Finland,
Juselius Foundation, Finnish Funding Agency for Technology and
Innovation (TEKES) and Finska La¨karesa¨llskapet.
Koistinen, H., Koistinen, R., Zhang, W.M., Valmu, L., and Stenman,
U.H. (2009). Nexin-1 inhibits the activity of human brain tryp-
sin. Neuroscience 160, 97–102.
References
Koivunen, E., Itkonen, O., Halila, H., and Stenman, U.H. (1990).
Cyst fluid of ovarian cancer patients contains high concentra-
tions of trypsinogen-2. Cancer Res. 50, 2375–2378.
Koivunen, E., Wang, B., Dickinson, C.D., and Ruoslahti, E. (1994).
Peptides in cell adhesion research. Methods Enzymol. 245,
346–369.
Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P.,
Heikkila¨, P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen,
Y.T., et al. (1999). Tumor targeting with a selective gelatinase
inhibitor. Nat. Biotechnol. 17, 768–774.
Kollman, P.A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong,
L., Lee, M., Lee, T., Duan, Y., Wang, W., et al. (2000). Calcu-
lating structures and free energies of complex molecules: com-
bining molecular mechanics and continuum models. Acc. Chem.
Res. 33, 889–897.
Krowarsch, D., Cierpicki, T., Jelen, F., and Otlewski, J. (2003).
Canonical protein inhibitors of serine proteases. Cell. Mol. Life
Sci. 60, 2427–2444.
Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z.,
Miller, W., and Lipman, D.J. (1997). Gapped BLAST and PSI-
BLAST: a new generation of protein database search programs.
Nucleic Acids Res. 25, 3389–3402.
Case, D.A., Cheatham, T.E., III, Darden, T., Gohlke, H., Luo, R.,
Merz, K.M., Jr., Onufriev, A., Simmerling, C., Wang, B., and
Woods, R.J. (2005). The Amber biomolecular simulation pro-
grams. J. Comput. Chem. 26, 1668–1688.
Chase, T.J. and Shaw, E. (1970). Titration of trypsin, plasmin, and
thrombin with p-nitrophenyl p9-guanidinobenzoate HCl. Meth-
ods Enzymol. 19, 20–27.
Chen, J.M. and Ferec, C. (2000). Genes, cloned cDNAs, and pro-
teins of human trypsinogens and pancreatitis-associated cationic
trypsinogen mutations. Pancreas 21, 57–62.
Coombs, G.S., Bergstrom, R.C., Pellequer, J.L., Baker, S.I., Navre,
M., Smith, M.M., Tainer, J.A., Madison, E.L., and Corey, D.R.
(1998). Substrate specificity of prostate-specific antigen (PSA).
Chem. Biol. 5, 475–488.
Lovgren, J., Tian, S., Lundwall, A., Karp, M., and Lilja, H. (1999).
Production and activation of recombinant hK2 with propeptide
mutations resulting in high expression levels. Eur. J. Biochem.
266, 1050–1055.
Mattsson, J.M., Valmu, L., Laakkonen, P., Stenman, U.H., and Kois-
tinen, H. (2008). Structural characterization and anti-angiogenic
properties of prostate-specific antigen isoforms in seminal fluid.
Prostate 68, 945–954.
Cornell, W.D., Cieplak, P., Bayly, C.I., Gould, I.R., Merz, K.M.,
Ferguson, D.M., Spellmeyer, D.C., Fox, T., Caldwell, J.W., and
Kollman, P.A. (1995). A second generation force field for the
simulation of proteins, nucleic acids, and organic molecules. J.
Am. Chem. Soc. 117, 5179–5197.
Cottrell, G.S., Amadesi, S., Grady, E.F., and Bunnett, N.W. (2004).
Trypsin IV, a novel agonist of protease-activated receptors 2 and
4. J. Biol. Chem. 279, 13532–13539.
Medveczky, P., Antal, J., Patthy, A., Kekesi, K., Juhasz, G., Szilagyi,
L., and Graf, L. (2006). Myelin basic protein, an autoantigen in
multiple sclerosis, is selectively processed by human trypsin 4.
FEBS Lett. 580, 545–552.
Nixon, A.E. (2002). Phage display as a tool for protease ligand
discovery. Curr. Pharm. Biotechnol. 3, 1–12.
Eichler, J. and Houghten, R.A. (1993). Identification of substrate-
analog trypsin inhibitors through the screening of synthetic pep-
tide combinatorial libraries. Biochemistry 32, 11035–11041.
Fang, R., Qi, J., Lu, Z.B., Zhou, H., Li, W., and Shen, J. (1996).
Selection of trypsin inhibitors in phage peptide library. Biochem.
Biophys. Res. Commun. 220, 53–56.
Brought to you by | Purdue University Libraries
Authenticated
Download Date | 5/23/15 10:18 PM